Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • More
    • Shopping
    • Flights
    • Travel
    • Hotels
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
  • Past 7 days
    • Any time
    • Past hour
    • Past 24 hours
    • Past 30 days
  • Most recent
    • Best match

News

The Lancet5d
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Copyright: © 2015 Elsevier Ltd. Published by Elsevier Ltd.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Trending now

On foreign steel tariffs
PBS sues Trump admin
On COVID vaccine for kids
Emmy-winning actress dies
Trump fires Kim Sajet
John Thrasher dies
Third suspect arrested
Canada wildfires spread
On Medicaid cuts
Lets revoke parole program
Vetoes rent algorithms ban
Jailed for selling daughter
Buys back first six albums
Mondelez sues Aldi
US govt. employee charged
Oval Office sendoff
McCullers hires security
US trade deficit narrows
SC mass shooting arrest
Sued over wrongful arrests?
DOJ cuts ABA judicial vetting
Cuts clean energy projects
Brand pleads not guilty
Feds probe impersonator
DOJ moves to dismiss case
Deaf Americans sue Trump
Tornado warnings in KY
On US-China trade talks
Paul Ingrassia to lead OSC
Nigeria floods
Sale reaches 2,500 strikeouts
US inflation gauge cools
Signs AI deal with Amazon
Feedback
© 2025 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices
  • Consumer Health Privacy